Clinical trials: Hypoplasminogenemia
Ligneous Conjunctivitis
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
Kedrion Human Plasminogen, a sterile human plasma-derived plasminogen preparation for topical ocular use will be evaluated for the indication of treatment of ligneous conjunctivitis.
- Trial name
- NCT01554956
- Testing
- Human Plasminogen
- Where
- 3 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Kedrion S.p.A.
Ligneous Conjunctivitis
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen…
- Trial name
- NCT04586062
- Testing
- Plasminogen
- Sponsor
- Kedrion S.p.A.
Hypoplasminogenemia
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring…
- Trial name
- NCT03642691
- Testing
- Ryplazim
- Where
- 3 sites in United States
- Sponsor
- Prometic Biotherapeutics, Inc.
Hypoplasminogenemia, Congenital Plasminogen Deficiency
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
This is a Phase 2/3 pivotal study to evaluate pharmacokinetics (PK), efficacy, and safety of Prometic Plasminogen (Human) Intravenous Lyophilized Solution, the investigational medicinal product (IMP), in pediatric and adult…
- Trial name
- NCT02690714
- Testing
- Plasminogen (Human) intravenous
- Where
- 2 sites in United States, Norway
- Volunteers
- 15 people
- Sponsor
- Prometic Biotherapeutics, Inc.
Type I Plasminogen Deficiency, Hypoplasminogenemia
A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
ProMetic is intiitating a first-in-man study entitled "A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children with Hypoplasminogenemia".
- Trial name
- NCT02312180
- Testing
- Plasminogen (Human) Intravenous
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Prometic Biotherapeutics, Inc.
Hypoplasminogenemia
A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous
These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia.
- Trial name
- NCT03265171
- Testing
- Plasminogen (Human)
- Sponsor
- Prometic Biotherapeutics, Inc.